Home » Topics » BioWorld Science

BioWorld Science
RSS

New MAP4K1 inhibitors identified at Ariad Pharmaceuticals

June 29, 2018

EMA committee recommends approval of Cablivi for aTTP

June 29, 2018

Phase III MEDALIST study of luspatercept meets primary and key secondary endpoints

June 29, 2018

ProQR initiates phase I/II WINGS trial of QR-313

June 29, 2018

Trevena completes first-in-human study of TRV-250 for treatment of acute migraine

June 29, 2018

Ziopharm initiates phase I trial of Ad-RTS-hIL-12 plus veledimex with nivolumab in recurrent GBM

June 29, 2018

INDIGO-1 study of gemcabene in severe hypertriglyceridemia meets primary endpoint

June 29, 2018

Arsanis discontinues phase II study of ASN-100

June 29, 2018

European Commission approves Xeljanz for active psoriatic arthritis

June 29, 2018

Researchers present preclinical data for [11C]NOP-46

June 29, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...